Q-omics provides the consensus-scored RBM34 profile across patient tissues and cancer cell-line models. RBM34 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RBM34 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, RBM34 protein abundance shows 27,134 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight ACC, KIRC, and LUAD as cancer lineages where RBM34 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBM34 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBM34 survival associations across molecular data types. RBM34 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBM34 RNA expression–survival associations across cancer types. High RBM34 expression shows unfavorable associations in ACC, KICH, LIHC, UVM and KIRC, but favorable associations in BLCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RBM34 RNA expression.
This table summarizes RBM34 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RBM34. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBM34 shows lower tumor expression in KICH and higher tumor expression in KIRC, BLCA, HNSC, LIHC and STAD. The KIRC box plot shows higher RBM34 RNA expression in tumor versus normal tissue (log2 FC = +0.231, t-test p < 0.001).
This table shows molecular features associated with RBM34 in patient tissues and cancer cell lines. In patient samples, RBM34 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, RBM34 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
